Recent scientific articles relevant to Sanfilippo Syndrome: July 2022, digest

August 15, 2022

Every week thousands of scientific articles on various topics are published. Here are some recent articles and abstracts that are relevant to understanding, managing, and/or treating Sanfilippo Syndrome (mucopolysaccharidosis III or MPS III) as of July 2022.

“Impaired mitophagy in Sanfilippo a mice causes hypertriglyceridemia and brown adipose tissue activation”

Published: Journal of Biological Chemistry, June 22, 2022

Authors: Miguel Tillo, William Lamanna, Chrissa Dwyer, Daniel Sandoval, Ariane Pessentheiner, Norah Al-Azzam, Stéphane Sarrazin, Jon Gonzales, Shih-Hsin Kan, Alexander Andreyev, Nicholas Schultheis, Bryan Thacker, Charles Glass, Patricia Dickson, Raymond Wang, Scott Selleck, Jeffrey Esko , Philip Gordts

Abstract: “Lysosomal storage diseases result in various developmental and physiological complications, including cachexia. To study the causes for the negative energy balance associated with cachexia, we assessed the impact of sulfamidase deficiency and heparan sulfate storage on energy homeostasis and metabolism in a mouse model of type IIIa mucopolysaccharidosis (MPS IIIa, Sanfilippo A syndrome). At 12-weeks of age, MPS IIIa mice exhibited fasting and postprandial hypertriglyceridemia compared with wildtype mice, with a reduction of white and brown adipose tissues. Partitioning of dietary [3H]triolein showed a marked increase in intestinal uptake and secretion, whereas hepatic production and clearance of triglyceride-rich lipoproteins did not differ from wildtype controls. Uptake of dietary triolein was also elevated in brown adipose tissue (BAT), and notable increases in beige adipose tissue occurred, resulting in hyperthermia, hyperphagia, hyperdipsia, and increased energy expenditure. Furthermore, fasted MPS IIIa mice remained hyperthermic when subjected to low temperature but became cachexic and profoundly hypothermic when treated with a lipolytic inhibitor. We demonstrated that the reliance on increased lipid fueling of BAT was driven by a reduced ability to generate energy from stored lipids within the depot. These alterations arose from impaired autophagosome-lysosome fusion, resulting in increased mitochondria content in beige and BAT. Finally, we show that increased mitochondria content in BAT and postprandial dyslipidemia was partially reversed upon 5-week treatment with recombinant sulfamidase. We hypothesize that increased BAT activity and persistent increases in energy demand in MPS IIIa mice contribute to the negative energy balance observed in patients with MPS IIIa.”

Read more: Access the publication

Source: All information is sourced directly from the scientific abstracts and articles published by the researchers.

Related Posts